Text Size

Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01636765
First received: July 9, 2012
Last updated: August 15, 2012
Last verified: August 2012
History of Changes
  Purpose

This is a study is to evaluate inter- and intra-rater reliability of the Clinician Erythema Assessment Scale. There is no treatment (intervention) associated with this study.


Condition Intervention
Erythema
Rosacea
 Drug: No Intervention

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Rosacea
U.S. FDA Resources

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Intra-rater Reliability of the CEA Scale [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Enrollment: 104
Study Start Date: May 2012
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Facial Erythema Associated with Rosacea
Patients with facial erythema associated with rosacea
 Drug: No Intervention
No Intervention

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with facial erythema related to rosacea

Criteria

Inclusion Criteria:

  • Rosacea

Exclusion Criteria:

  • Unwilling to remove all facial make-up
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01636765

Locations
United States, Texas
Austin, Texas, United States
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan
  More Information

No publications provided

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01636765     History of Changes
Other Study ID Numbers: 199201-003
Study First Received: July 9, 2012
Last Updated: August 15, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Rosacea
Erythema
Skin Diseases

ClinicalTrials.gov processed this record on May 22, 2013